Infliximab Remicade

Most Common Remicade Infliximab Side Effects

Abdominal pain ; cough ; dizziness ; sneezing ; fainting ; headache ; muscle pain ; nasal congestion ; nausea ; runny nose ;

shortness of breath ; sore throat ; tightness in chest ; unusual tiredness or weakness ; vomiting ;wheezing

Less Common Remicade (Infliximab) Side Effects

Back pain ; bloody or cloudy urine ; cracks in skin at the corners of mouth ; diarrhea difficult or; painful urination ; frequent urge to urinate ; high blood pressure ; low blood pressure ; pain

pain or tenderness around eyes and cheekbones ; skin rash ;soreness or irritation of mouth or tongue ; soreness or redness around fingernails or toenails ; vaginal burning or itching and discharge ; white patches in mouth and/or on tongue

Crohn's Disease Remicade or Fistulizing Crohn's Disease and Infliximab - The recommended dose of  Remicade is 5 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of adults with moderately to severely active Crohn's disease or fistulizing Crohn's disease. For adult patients who respond and then lose their response, consideration may be given to treatment with 10 mg/kg. Patients who do not respond by week 14 are unlikely to respond with continued dosing and consideration should be given to discontinue REMICADE in these patients.
 

Remicade Arthritis - Rheumatoid -  Remicade in combination with methotrexate, is indicated for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis.

Remicade Arthritis - Psoriatic :  Remicade is indicated for reducing the sings and symptoms of active arthritis by inhibiting the progression of structural damage and improving physicial function in patients with psoriatic arthritis.

Ulcerative Colitis - REmicade is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.

____________________________

Remicade injection  - lyophilized concentrate for IV injection is supplied in individually-boxed single-use vials in the following strength:

NDC 57894-030-01.......................100 mg infliximab in a 20 mL vial